Pembrolizumab (Keytruda) for Renal Cell Carcinoma — Details


( Last Updated : April 20, 2020)
Generic Name:
Pembrolizumab
Project Status:
Complete
Therapeutic Area:
Renal Cell Carcinoma (RCC)
Manufacturer:
Merck Canada
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0185-000
NOC Status at Filing:
Pre NOC
NOC Date:

Details


Strength:
25 mg/mL & 50 mg/vial
Tumour Type:
Genitourinary
Indications:
Renal Cell Carcinoma
Funding Request:
For the treatment of patients with advanced renal cell carcinoma (RCC) in combination with axinitib, as first-line treatment.
Pre Noc Submission:
Yes
Sponsor:
Merck Canada
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.